Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-06-28 Major Shareholding Noti…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 97% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals plc' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE'. This type of disclosure relates to insider/significant shareholder dealings during a takeover situation. Among the provided categories, 'Director's Dealing (Code: DIRS)' is the closest fit, as it covers personal share transactions by executives/insiders, although Form 8.3 is specifically related to Takeover Code disclosures, which often involve significant shareholders or parties to an offer, rather than just routine director trades. However, since there is no specific code for 'Takeover Disclosure of Interests/Dealings', DIRS is the most appropriate classification for reporting personal security interests/dealings by involved parties. The document details positions and derivative transactions (dealings) related to an offer involving Dechra Pharmaceuticals plc.
2023-06-28 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains detailed tables regarding voting rights, financial instruments, and shareholder positions, referencing DTR rules. This structure is characteristic of a regulatory filing notifying a change in major shareholding thresholds. The presence of 'RNS Number' and the closing statement referencing the 'London Stock Exchange' and 'Financial Conduct Authority' confirms its nature as a regulatory disclosure. The specific content aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2023-06-28 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals plc" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is a Public Opening Position Disclosure/Dealing Disclosure by a person holding 1% or more interests in relevant securities during a takeover situation. This type of disclosure relates to insider dealings or significant ownership changes during a M&A event, which falls under the scope of takeover activity. While it involves dealing disclosure (similar to DIRS), the specific context of Rule 8.3 of the Takeover Code strongly links it to M&A activity (TAR) or a specific regulatory filing related to that activity. Since the definitions provided do not have a specific code for 'Takeover Disclosure Form 8.3', I must choose the closest fit. Director's Dealing (DIRS) covers personal share transactions by directors, but this is a major shareholder/controller disclosure during a takeover. Transaction in Own Shares (POS) is for the company buying back shares. Major Shareholding Notification (MRQ) is for crossing ownership thresholds, but this is specifically tied to the Takeover Code. Given the context of a takeover bid (implied by the Takeover Code reference) and the disclosure of interests/dealings related to that bid, the most appropriate category among the choices is M&A Activity (TAR), as these disclosures are mandatory during such events. However, Form 8.3 is a specific regulatory filing mandated by the UK Takeover Panel. If it were a general regulatory announcement not fitting elsewhere, RNS would be used. Since it is a specific disclosure related to a potential takeover, TAR is the best fit for the underlying economic event being reported on.
2023-06-27 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled "FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is used to disclose interests and dealings in securities during a takeover situation. This type of disclosure, related to insider/significant shareholder activity during a takeover bid, is a specific type of regulatory filing concerning director/insider dealings or major shareholding changes, but the context of the Takeover Code makes it highly specific. Since the definitions provided do not have a specific code for 'Takeover Code Disclosure' or 'Form 8.3', we must evaluate the closest fit. It involves director/insider activity (like DIRS) and major shareholding changes (like MRQ), but the primary driver is the takeover context. Given the options, 'Director's Dealing' (DIRS) covers personal share transactions by executives, and 'Major Shareholding Notification' (MRQ) covers changes in significant ownership. Since this form reports the position and dealings of a significant shareholder (Millennium International Management LP) in relation to an offer for Dechra Pharmaceuticals plc, it most closely aligns with reporting significant ownership changes related to corporate action, which is covered by MRQ (Major Shareholding Notification) or DIRS (Director's Dealing). However, Form 8.3 is a mandatory disclosure under the UK Takeover Code for parties holding 1% or more during an offer period. This is a specific regulatory disclosure about share ownership and dealings during a takeover. Given the options, 'Director's Dealing' (DIRS) is the closest fit for reporting personal/controlled security interests and transactions, even though the filer is an investment manager, not strictly a director. If a more specific takeover code filing existed, that would be chosen. Lacking that, DIRS captures the essence of reporting security interests/dealings by an interested party. Alternatively, RNS is the fallback, but DIRS is more specific to the content type (insider/significant holder dealing). I will classify it as DIRS as it details interests and dealings of a significant party involved in the securities of the offeree.
2023-06-26 English
Scheme Document - Recommended cah acquisition of Dechra by Freya Bidco Ltd
M&A Activity Classification · 98% confidence The document explicitly details a 'RECOMMENDED CASH ACQUISITION' of 'DECHRA PHARMACEUTICALS PLC' by 'FREYA BIDCO LIMITED' to be effected by a 'scheme of arrangement under Part 26 of the 2006 Act'. This structure, involving a formal offer, explanatory statements, court meetings, and general meetings related to a takeover, is characteristic of documents filed under UK takeover regulations. The key action is a proposed takeover/merger. This aligns directly with the definition for M&A Activity (Code: TAR). Although it contains elements related to shareholder voting (AGM/Proxy), the primary purpose is the announcement and explanation of the takeover proposal itself.
2023-06-26 English
Postponement of results
Report Publication Announcement Classification · 99% confidence The document is a short announcement (1878 characters) released via RNS (Regulatory News Service) from Dechra Pharmaceuticals PLC. The core content is the 'Postponement of the Announcement of the Results for the Financial Year ended 30 June 2023'. This is not the results themselves (ER or IR), nor is it a formal proxy or annual report. It is a regulatory update concerning the timing of a future report release. Since it is a general regulatory announcement distributed through the RNS system and concerns a procedural update rather than fitting into a highly specific category like DIRS, DIV, or MANG, the most appropriate classification is the general regulatory filing category, RNS, as per Rule 2 (Menu vs Meal) and Rule 3 (Fallback).
2023-06-26 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.